<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of kidney replacement therapy for children with chronic kidney disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of kidney replacement therapy for children with chronic kidney disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of kidney replacement therapy for children with chronic kidney disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bradley A Warady, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rukshana Shroff, MD, FRCPCH, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tej K Mattoo, MD, DCH, FRCP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 01, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H118550482"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Pediatric chronic kidney disease (CKD) is a chronic, progressive disorder. As the estimated glomerular filtration rate (GFR) declines to less than 30 mL/min per 1.73 m<sup>2</sup> (CKD stage 4), preparations for kidney replacement therapy (KRT) are needed [<a href="#rid1">1</a>]. The family/caregiver and, if appropriate, the child should be provided with information related to options for KRT. These include preemptive kidney transplantation, peritoneal dialysis (PD), and hemodialysis (HD).</p><p>KRT options and timing of KRT for children with CKD are reviewed here.</p><p>Topic reviews that include more comprehensive descriptions of the different forms of KRT for pediatric CKD, including complications and outcome, are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14562.html" rel="external">"Hemodialysis for children with chronic kidney disease"</a> and  <a class="medical medical_review" href="/z/d/html/16400.html" rel="external">"Chronic peritoneal dialysis in children"</a> and  <a class="medical medical_review" href="/z/d/html/6120.html" rel="external">"Kidney transplantation in children: General principles"</a> and  <a class="medical medical_review" href="/z/d/html/6143.html" rel="external">"Kidney transplantation in children: Complications"</a>.)</p><p class="headingAnchor" id="H319170698"><span class="h1">STAGING CHRONIC KIDNEY DISEASE</span><span class="headingEndMark"> — </span>Assessing kidney function is dependent on the age of the child, as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children two years of age and older</strong> – For children two years of age and older, the severity of CKD is categorized into stages based on estimated glomerular filtration rate (GFR)  (<a class="graphic graphic_table graphicRef89808" href="/z/d/graphic/89808.html" rel="external">table 1A</a>) [<a href="#rid2">2</a>]. End-stage kidney disease (ESKD) is categorized as stage G5 with a GFR below 15 mL/min per 1.73 m2. (See  <a class="medical medical_review" href="/z/d/html/6115.html" rel="external">"Chronic kidney disease in children: Definition, epidemiology, etiology, and course", section on 'Staging: Risk stratification'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children under two years of age</strong> – Children under two years of age do not fit within the above classification system, because they normally have a low GFR even when corrected for body surface area. In these patients, estimated GFR based upon serum creatinine can be compared with normative age-appropriate values to detect kidney impairment  (<a class="graphic graphic_table graphicRef116099" href="/z/d/graphic/116099.html" rel="external">table 1B</a>). A GFR value &gt;1 standard deviation below the mean should raise concern and prompt more intensive monitoring [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/z/d/html/6115.html" rel="external">"Chronic kidney disease in children: Definition, epidemiology, etiology, and course", section on 'Estimated glomerular filtration rate'</a>.)</p><p></p><p>In children, the level of proteinuria and eGFR have been used to characterize the timeline of CKD progression [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/z/d/html/6115.html" rel="external">"Chronic kidney disease in children: Definition, epidemiology, etiology, and course", section on 'Evaluation of proteinuria'</a>.)</p><p>Classification of CKD in children, including calculation of GFR and evaluation of proteinuria, is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6115.html" rel="external">"Chronic kidney disease in children: Definition, epidemiology, etiology, and course"</a>.)</p><p class="headingAnchor" id="H227966382"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H3049865639"><span class="h2">Chronic kidney disease stage 5 (end-stage kidney disease)</span><span class="headingEndMark"> — </span>In well-resourced countries, KRT is typically initiated in children with CKD stage 5 (also referred to as end-stage kidney disease [ESKD]). Although ESKD is relatively uncommon among children around the world, reported incidence rates vary depending on the country, from 1.9 to 18 per million childhood population. [<a href="#rid4">4,5</a>]. This variability is primarily due to global differences in the ability to diagnosis and manage children with significant kidney impairment in various parts of the world, as well as genetic and environmental factors [<a href="#rid4">4</a>]. Resource-abundant countries are more likely to possess the necessary resources for the detection and treatment of ESKD. The incidence of ESKD increases with age, with the highest incidence in adolescence [<a href="#rid5">5,6</a>].</p><p>The epidemiology of ESKD in children is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6115.html" rel="external">"Chronic kidney disease in children: Definition, epidemiology, etiology, and course", section on 'Epidemiology'</a>.)</p><p class="headingAnchor" id="H2943951326"><span class="h2">Kidney replacment therapy</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incidence</strong> – Globally, most children receiving KRT live in Europe, the United States, Australia/New Zealand and Japan [<a href="#rid7">7</a>]. The incidence of KRT initiation for ESKD is reported for the following regions:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>United States – In the United States, the incidence of starting KRT for pediatric ESKD is approximately 12 patients per million children, which represented 912 new patients 0 to 17 years old in 2020 [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Europe – In Europe in 2011, the incidence was 28 per 1 million age-related population [<a href="#rid8">8</a>]. In the United Kingdom, the number of children starting KRT has been stable with an incidence of new patients between 9 and 10 per million children [<a href="#rid9">9,10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence</strong> – The overall worldwide prevalence of KRT has increased due to improved survival with reported ranges from 18 to 100 per 1 million age-related population [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use of KRT modalities</strong> – KRT modalities for children with CKD include kidney transplantation, hemodialysis (HD), and peritoneal dialysis (PD).</p><p></p><p>The choice of KRT varies, particularly with age and resources. Data worldwide has shown that PD is the most common <strong>initial</strong> KRT therapy in children nine years and younger, and HD for patients aged 10 years and older [<a href="#rid6">6,8,11,12</a>]. In the United States, PD is the most common initial dialysis modality for children younger than five years. However, over time, kidney transplantation becomes the preferred choice of KRT as children transition from initial dialysis to transplantation [<a href="#rid6">6,9,13</a>].</p><p>Details of the different KRT modalities are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6120.html" rel="external">"Kidney transplantation in children: General principles"</a> and  <a class="medical medical_review" href="/z/d/html/14562.html" rel="external">"Hemodialysis for children with chronic kidney disease"</a> and  <a class="medical medical_review" href="/z/d/html/16400.html" rel="external">"Chronic peritoneal dialysis in children"</a>.)</p><p class="headingAnchor" id="H74638435"><span class="h1">ETIOLOGY</span><span class="headingEndMark"> — </span>The most common cause of pediatric end-stage kidney disease (ESKD) requiring KRT is congenital anomalies of the kidney and urinary tract (CAKUT). The proportion of cases with CAKUT decreases with increasing age due to the increased incidence of acquired glomerular disease  (<a class="graphic graphic_figure graphicRef68637" href="/z/d/graphic/68637.html" rel="external">figure 1</a>) [<a href="#rid14">14-16</a>]. The etiology of CKD and CAKUT are discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/6115.html" rel="external">"Chronic kidney disease in children: Definition, epidemiology, etiology, and course", section on 'Etiology'</a> and  <a class="medical medical_review" href="/z/d/html/6110.html" rel="external">"Overview of congenital anomalies of the kidney and urinary tract (CAKUT)"</a>.)</p><p class="headingAnchor" id="H3094809435"><span class="h1">WHEN TO PREPARE FOR KIDNEY REPLACEMENT THERAPY</span><span class="headingEndMark"> — </span>We start preparing the child and the family for KRT as the estimated glomerular filtration rate (GFR) declines to &lt;30 mL/min per 1.73 m<sup>2</sup> (CKD stage 4) [<a href="#rid1">1</a>]. Preparation includes educating the family/caregivers and child regarding KRT options (preemptive kidney transplantation, peritoneal dialysis [PD], and hemodialysis [HD]). (See  <a class="medical medical_review" href="/z/d/html/6085.html" rel="external">"Chronic kidney disease in children: Overview of management", section on 'Preparation for kidney failure'</a>.)</p><p class="headingAnchor" id="H363124528"><span class="h1">PREEMPTIVE TRANSPLANTATION AS PREFERRED KIDNEY REPLACEMENT THERAPY MODALITY</span></p><p class="headingAnchor" id="H1110402905"><span class="h2">Benefits of transplantation over dialysis</span><span class="headingEndMark"> — </span>For children with ESRD requiring KRT, we prefer kidney transplantation to any form of dialysis due to multiple factors, including:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Decreased mortality rates</strong> – Globally, all-cause mortality rates for children who have received a transplant are significantly lower than for those on dialysis. As an example, a study from the Australia and New Zealand Dialysis and Transplant registry of patients receiving KRT revealed mortality rates of 4.8, 5.9, and 1.1 per 100 patient years for children receiving hemodialysis (HD), peritoneal dialysis (PD), and a functioning transplant, respectively [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1">Additionally, a study from a large national database of children with end-stage kidney disease (ESKD), the United States Renal Data System (USRDS), reported first-year mortality rates per 1000 person-years of 30.2, 34.2, and 17.3 for PD, HD, and transplant patients, respectively [<a href="#rid6">6</a>]. Survival probability at five years was calculated as 81, 86, and 96 percent for HD, PD, and transplant patients, respectively. The expected remaining lifetime for males and females (ages 0 to 14 years) was estimated to be 18.8 years for dialysis patients versus 62.2 for transplant recipients and 72.8 years for the general population.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Better outcomes for kidney transplantation</strong> – Kidney transplantation is associated with better outcomes in health-related quality of life measures, growth, and development than either HD or PD [<a href="#rid18">18</a>]. Transplantation is less disruptive to family lifestyle, schooling, and social interactions than dialysis. In addition, transplantation avoids the dietary and fluid restrictions necessary while on dialysis and preserves vascular and peritoneal access sites for future use if the transplant should fail.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increased risks of dialysis</strong> – Dialysis is associated with an increased risk of cardiovascular disease (eg, ischemic heart disease, cerebrovascular disease, heart failure, cardiac arrest/arrhythmias, cardiomyopathy) [<a href="#rid19">19</a>] and vascular calcification, which occur at a proportionately earlier age. (See  <a class="medical medical_review" href="/z/d/html/7222.html" rel="external">"Vascular calcification in chronic kidney disease"</a>.)</p><p></p><p class="headingAnchor" id="H3238185347"><span class="h2">Timing of transplantation</span><span class="headingEndMark"> — </span>We prefer transplantation performed prior to the need for dialysis because mortality is lower in patients who receive preemptive transplantation than in those undergoing chronic dialysis [<a href="#rid18">18,19</a>]. We start preparing the patient and family/caregivers for transplant as the glomerular filtration rate (GFR) declines to &lt;30 mL/min per 1.73 m<sup>2</sup> (CKD stage 4). However, the exact timing for transplant varies depending on individual patient factors.</p><p>Limited data also suggest that renal allograft survival is better for children who received a pre-emptive transplant as initial KRT versus dialysis. In a retrospective study from the United Kingdom Transplant Registry of 2038 pediatric kidney transplant recipients, the five-year allograft survival was 91, 87, and 86 percent for the pre-emptively transplanted, initial PD, and initial HD groups, respectively [<a href="#rid20">20</a>].</p><p>Preemptive transplantation is more easily accomplished in children than in adults because of the availability of parental donors in many cases who are a haplotype match, are relatively young and healthy, and are frequently willing to donate a kidney. In addition, because pediatric nephrologists generally follow their patients from the early stages of CKD, they can more easily prepare the patient and their family for transplantation and avoid initiating dialysis. If a living related donor is not available, many countries prioritize children on the deceased donor transplant waiting list.</p><p>Despite these advantages, preemptive transplantation is still not achieved in the majority of children with ESKD, because they may present in CKD stage 5 with insufficient preparatory time required for transplantation prior to the need for dialysis or because transplantation is not possible or advisable due to small size, comorbidity, nonadherence to medical therapy, family instability, or other factors.</p><p>Preemptive transplantation has increasingly become the initial choice of treatment for pediatric ESKD.</p><p class="bulletIndent1"><span class="glyph">●</span>Europe – Preemptive transplantation has increased from 12 percent of European children who received KRT to 20 percent in 2016 [<a href="#rid5">5,21</a>]. In the United Kingdom, rates of preemptive kidney transplantation have increased to 36 percent [<a href="#rid5">5,8,9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Australia and New Zealand – Up to 22 percent of children in Australia and New Zealand receive a preemptive transplant [<a href="#rid12">12,22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>North America – In North America, the rate was 14.38 percent in 2020 compared with 17.4 percent in 2019, based on data from the USRDS 2022 Annual Data Report [<a href="#rid6">6</a>]. The lower rate that year may be the result of disruptions in care during the COVID-19 pandemic.</p><p></p><p class="headingAnchor" id="H3378955787"><span class="h1">DIALYSIS AS AN ALTERNATIVE KIDNEY REPLACEMENT THERAPY MODALITY</span></p><p class="headingAnchor" id="H1292327205"><span class="h2">Choosing a dialysis modality</span><span class="headingEndMark"> — </span>When preemptive transplantation is not an option, we choose between hemodialysis (HD) and peritoneal dialysis (PD). To make this choice, we use a multiprofessional team to carefully evaluate the family’s social, psychological, and economic background. Ideally this team includes the family physician, nephrologist, dialysis nurse, psychologist, and a social worker [<a href="#rid23">23-25</a>]. We base our decision on the following factors:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient age and size</strong> – In infants and young children, we prefer PD because it is technically easier to perform than HD, does not require a vascular access or venipuncture, and allows for a more liberal fluid intake [<a href="#rid26">26,27</a>]. In school-age children, home dialysis therapies, such as PD with the use of an automated PD cycling device, also facilitates regular school attendance. (See  <a class="medical medical_review" href="/z/d/html/14562.html" rel="external">"Hemodialysis for children with chronic kidney disease"</a> and  <a class="medical medical_review" href="/z/d/html/16400.html" rel="external">"Chronic peritoneal dialysis in children", section on 'Peritoneal dialysis versus hemodialysis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Comorbidities</strong> – We prefer PD over HD when there are contraindications to the use of anticoagulation and in children who have cardiovascular instability.</p><p></p><p class="bulletIndent1">The only absolute contraindications to PD include conditions that affect the integrity of the abdominal cavity and peritoneum (ie, omphalocele, gastroschisis, obliterated peritoneal cavity)  (<a class="graphic graphic_table graphicRef141890" href="/z/d/graphic/141890.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/16400.html" rel="external">"Chronic peritoneal dialysis in children", section on 'Contraindications to CPD'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Technical, social, and compliance issues</strong> – We often prefer home dialysis (PD or HD) over dialysis at a medical center, as it has less impact on time away from family, school and friends. However, home dialysis may not be possible if the family is unable to provide adequate care. In these families, choice is dictated by the dialytic modality available for children at a nearby center. We also consider proximity to a pediatric HD center, as well as the ability to achieve and maintain suitable vascular access, when counselling families about different dialysis modalities available. For those who live a long distance from a HD center, home dialysis means that the family does not need to travel to the unit three or more times per week for treatments. (See  <a class="medical medical_review" href="/z/d/html/1875.html" rel="external">"Home hemodialysis (HHD): Establishment of a program"</a> and  <a class="medical medical_review" href="/z/d/html/14562.html" rel="external">"Hemodialysis for children with chronic kidney disease", section on 'Home hemodialysis'</a>.)</p><p></p><p class="bulletIndent1">We recognize the tremendous burden of care that families experience with home-based dialysis therapy. In addition to the burden associated with the dialysis procedure itself, for those patients who receive PD there is the burden associated with decisions regarding the type of PD solution daily, concern about complications particularly peritonitis and drain pain, and safely managing machine errors [<a href="#rid28">28,29</a>]. Families must be made fully aware of the burden of care involved with performing PD as part of the modality selection process so that appropriate support systems may be put in place.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient and parent/caregiver preference</strong> – We discuss the selection of a dialysis modality with the child and their parents/caregivers, and we respect the child and parents/caregivers’ choice as long as there are no clear drawbacks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preservation of dialysis access</strong> – We always consider the importance of preserving dialysis access (the PD catheter for the PD patient and either the HD catheter or fistula for the HD patient) when selecting the optimal dialysis modality for a child.</p><p></p><p>The choice between the two modalities varies worldwide, as limited data suggests similar five-year mortality between the two modalities in children [<a href="#rid30">30,31</a>]. In a study of data from the Italian Registry of Pediatric Chronic Dialysis, outcomes were compared between 310 children on PD or HD who were propensity-matched based on gender, age, primary cause of end-stage kidney disease (ESKD) and comorbidities [<a href="#rid31">31</a>]. Mortality rates at two-year follow-up and rates of transplantation three years after dialysis initiation were similar between groups. Although there was a lower mortality rate for patients on HD at five-year follow-up, the very low event rate and potential for selection bias limit confidence in this finding. In this cohort, patients who were initiated on PD compared with those on HD were more likely to be younger, have a diagnosis of a congenital anomalies of the kidney and urinary tract (CAKUT), and have a higher urinary output. Further data are needed to determine if the choice of modality affects long-term outcome.</p><p>There are also no studies to suggest that either PD or HD is otherwise superior in children with ESKD [<a href="#rid32">32</a>]. International registries suggest that PD is the preferred and most widely used modality in younger children (in those less than five years in the United Kingdom renal replacement registry, European Society for Pediatric Nephrology registry, and United States Renal Data System [USRDS] registry). Data from the USRDS demonstrates that between 2016 to 2020, 50 percent of patients aged one to five years received PD as their initial renal replacement therapy, in contrast with only 30.7 percent of those aged 6 to 12 years [<a href="#rid6">6</a>]. The use of PD has increased in lower- and middle-income countries, both in children and adults [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H2374951967"><span class="h2">Planning for dialysis</span><span class="headingEndMark"> — </span>Planning for initiation of dialysis is dependent upon the chosen modality.</p><p class="headingAnchor" id="H492370276"><span class="h3">Hemodialysis</span><span class="headingEndMark"> — </span>Children who are to receive HD need evaluation for vascular access. Vascular access options include arteriovenous (AV) fistula or a central venous tunneled catheter. AV fistulae require time to mature prior to use, which may be several weeks to months. As a result, if an AV fistula is chosen, it ideally needs to be established several weeks to months prior to the initiation of dialysis. As in adults, the "fistula first" policy applies to children as well, as AV fistulae are associated with a lower incidence of complications compared with catheters [<a href="#rid34">34,35</a>]. The use of a central venous catheter, which is associated with a greater rate of infectious complications when compared with AV fistulae, should ideally be reserved for patients too small to permit surgical construction of a fistula or when there is an expectation for expeditious (&lt;1 year) kidney transplantation [<a href="#rid36">36,37</a>]. The need for increased attention to advanced proactive planning for placement and maturation of an AV fistula (optimal vascular access) is reflected by the finding that most pediatric patients (81 percent) in the United States initiate HD with a central venous catheter [<a href="#rid38">38</a>]. (See  <a class="medical medical_review" href="/z/d/html/14562.html" rel="external">"Hemodialysis for children with chronic kidney disease", section on 'Vascular access'</a>.)</p><p class="headingAnchor" id="H3401235465"><span class="h3">Peritoneal dialysis</span><span class="headingEndMark"> — </span>Children who are to initiate PD need to undergo abdominal surgery for placement of a PD catheter. Use of a double cuff catheter and perioperative antibiotic prophylaxis within 60 minutes prior to the incision for catheter placement has been associated with fewer infectious complications of PD [<a href="#rid39">39,40</a>]. Ideally, there should be ample time for the abdominal wound to heal prior to the initiation of dialysis, thereby avoiding complications of leaking and infection. The minimum timeframe for healing is approximately two weeks. Absolute and relative contraindications to PD are included in the related table  (<a class="graphic graphic_table graphicRef141890" href="/z/d/graphic/141890.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/16400.html" rel="external">"Chronic peritoneal dialysis in children"</a>.)</p><p class="headingAnchor" id="H859626767"><span class="h2">Timing of dialysis initiation</span><span class="headingEndMark"> — </span>The timing of dialysis initiation is a complex decision that should take into account the estimated glomerular filtration rate (GFR) as well as signs and symptoms of uremia. We initiate some form of KRT in children when the GFR falls below 15 mL/min per 1.73 m<sup>2</sup> (CKD stage 5)  (<a class="graphic graphic_table graphicRef89808" href="/z/d/graphic/89808.html" rel="external">table 1A</a>). At that level of kidney function or below, the classical clinical indications for dialysis (ie, uremic symptoms) present, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Fluid overload (ie, inability to maintain euvolemia with development of hypertension and/or significant peripheral edema)</p><p class="bulletIndent1"><span class="glyph">●</span>Deterioration in nutritional status and/or growth failure with declining weight and/or height percentiles</p><p class="bulletIndent1"><span class="glyph">●</span>Uncontrolled metabolic abnormalities (eg, hyperkalemia, hyperphosphatemia, acidosis)</p><p class="bulletIndent1"><span class="glyph">●</span>Subjective complaints of the patient (eg, loss of appetite, nausea, fatigue, inability to concentrate, perceived poor quality of life)</p><p></p><p>We make the decision to start dialysis as part of a discussion between the patient (if age appropriate), their parents/caregivers, and their healthcare providers. We only start dialysis once we’ve determined that these conditions are persistent and refractory to medication and/or dietary management. The duration of uremic symptoms before we decide dialysis is necessary depends on their severity as well as the distress they are causing the child. In general, we prioritize the severity of uremic symptoms and the distress they are causing the child over the GFR.</p><p>In Europe, the United States, and Canada, the average GFR at the time of commencement of KRT is 8 to 9 mL/min/1.73 m<sup>2</sup>, although there is a wide variation between centers [<a href="#rid8">8,41,42</a>]. A randomized controlled trial in adults has shown that starting dialysis at higher levels of GFR is associated with worse outcomes, and there is evidence that this is the case in children too [<a href="#rid43">43-46</a>]. Methods of estimating GFR, including circumstances in which the estimated GFR may be inaccurate, are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6115.html" rel="external">"Chronic kidney disease in children: Definition, epidemiology, etiology, and course", section on 'Glomerular filtration rate'</a>.)</p><p>KRT may be initiated earlier in children with CKD at a higher GFR primarily to permit the provision of the nutritional needs necessary to maintain normal (or near normal) growth. As noted above, preemptive kidney transplantation is the preferred modality, as it is the intervention that provides the best outcomes regarding growth, development, quality of life, and patient survival. On the other hand, some children with continued good urine volumes can be maintained off dialysis for a substantial period of time with very low GFRs if strict attention is paid to growth, nutrition, and therapeutic control of metabolic abnormalities. There is no evidence that either approach is better. (See <a class="local">'Preemptive transplantation as preferred kidney replacement therapy modality'</a> above.)</p><p>For patients who undergo dialysis as the initial KRT, earlier indications for intervention prior to CKD stage 5 may include:</p><p class="bulletIndent1"><span class="glyph">●</span>Children with nephrotic syndrome requiring bilateral nephrectomies pretransplant.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Correction of metabolic abnormalities that fail medical management including hyperkalemia, hyperphosphatemia, and metabolic acidosis. (See  <a class="medical medical_review" href="/z/d/html/128353.html" rel="external">"Chronic kidney disease in children: Complications", section on 'Hyperkalemia'</a> and  <a class="medical medical_review" href="/z/d/html/128353.html" rel="external">"Chronic kidney disease in children: Complications", section on 'Metabolic acidosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inadequate nutrition because of fluid limitations. This is especially an issue with infants who are maintained on a completely liquid diet (ie, formula or breast milk). In these patients, dialysis is instituted to allow the required volume of feeds to maintain adequate growth.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension that is refractory to dietary sodium restriction and medications.</p><p></p><p class="headingAnchor" id="H2807043532"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110751.html" rel="external">"Society guideline links: Chronic kidney disease in children"</a>.)</p><p class="headingAnchor" id="H60773527"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – In well-resourced countries, kidney replacement therapy (KRT) is typically initiated in children with chronic kidney disease (CKD) stage 5 glomerular filtration rate (GFR; below 15 mL/min per 1.73 m<sup>2</sup>)  (<a class="graphic graphic_table graphicRef89808" href="/z/d/graphic/89808.html" rel="external">table 1A</a>), also referred to as end-stage kidney disease (ESKD). Globally, the reported incidence for ESKD ranges from 4 to 18 per million children worldwide. This variability is thought to be due to global differences in the ability to detect ESKD and the resources to provide KRT, as well as genetic and environmental factors. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiology</strong> – The most common cause of pediatric ESKD is congenital anomalies of the kidney and urinary tract (CAKUT). The proportion of cases with CAKUT decreases with increasing age due to the increasing incidence of acquired glomerular disease  (<a class="graphic graphic_figure graphicRef68637" href="/z/d/graphic/68637.html" rel="external">figure 1</a>). (See  <a class="medical medical_review" href="/z/d/html/6115.html" rel="external">"Chronic kidney disease in children: Definition, epidemiology, etiology, and course", section on 'Etiology'</a> and  <a class="medical medical_review" href="/z/d/html/6110.html" rel="external">"Overview of congenital anomalies of the kidney and urinary tract (CAKUT)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>When to prepare for KRT</strong> – For children with CKD, we start preparing for KRT when their GFR falls below 30 mL/min per 1.73 m<sup>2</sup> (CKD stage 4  (<a class="graphic graphic_table graphicRef89808 graphicRef116099" href="/z/d/graphic/89808.html" rel="external">table 1A-B</a>)). This includes educating the family/caregivers and child regarding KRT options (preemptive kidney transplantation, peritoneal dialysis [PD], and hemodialysis [HD]).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preemptive kidney transplantation as preferred KRT modality</strong> – We prefer transplantation performed prior to the need for dialysis because long-term outcomes (eg, growth, development, quality of life, and mortality) in patients who receive preemptive transplantation are better than in those undergoing chronic dialysis. (See <a class="local">'Preemptive transplantation as preferred kidney replacement therapy modality'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dialysis as an alternative KRT modality</strong> – When preemptive transplantation is not an option, we choose between HD and PD. We make this choice with a multiprofessional team in consultation with the patient and family/caregivers. It is based on multiple factors, including technical, social, and compliance issues, and family preference. (See <a class="local">'Dialysis as an alternative kidney replacement therapy modality'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Timing of dialysis initiation</strong> – In some children, we occasionally initiate dialysis before GFR falls below 15 mL/min per 1.73 m<sup>2</sup> (CKD stage 5), primarily to maintain normal growth and to manage metabolic abnormalities that are unresponsive to other medical interventions. However, some children, and in particular, infants, with maintained urine output may continue without dialysis for years if attention is paid to their nutritional and therapeutic management. (See <a class="local">'Timing of dialysis initiation'</a> above.)</p><p></p><p class="headingAnchor" id="H2493365218"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>We are saddened by the death of Lesley Rees, MD, FRCPCH, who passed away in May 2022. UpToDate acknowledges Dr. Rees's past work as an author for this topic.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39:S1.</a></li><li><a class="nounderline abstract_t">KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013; 3:136.</a></li><li><a class="nounderline abstract_t">Furth SL, Pierce C, Hui WF, et al. Estimating Time to ESRD in Children With CKD. Am J Kidney Dis 2018; 71:783.</a></li><li><a class="nounderline abstract_t">Harambat J, van Stralen KJ, Kim JJ, Tizard EJ. Epidemiology of chronic kidney disease in children. Pediatr Nephrol 2012; 27:363.</a></li><li><a class="nounderline abstract_t">Bonthuis M, Vidal E, Bjerre A, et al. Ten-year trends in epidemiology and outcomes of pediatric kidney replacement therapy in Europe: data from the ESPN/ERA-EDTA Registry. Pediatr Nephrol 2021; 36:2337.</a></li><li class="breakAll">USRDS 2022 Annual Report. https://usrds-adr.niddk.nih.gov/2022 (Accessed on July 23, 2023).</li><li><a class="nounderline abstract_t">Ploos van Amstel S, Noordzij M, Warady BA, et al. Renal replacement therapy for children throughout the world: the need for a global registry. Pediatr Nephrol 2018; 33:863.</a></li><li><a class="nounderline abstract_t">Harambat J, Bonthuis M, Groothoff JW, et al. Lessons learned from the ESPN/ERA-EDTA Registry. Pediatr Nephrol 2016; 31:2055.</a></li><li class="breakAll">Pruthi R, Hamilton AJ, O’Brien C, et al. UK Renal Registry 17th Annual Report: Chapter 4 Demography of the UK Paediatric Renal Replacement Therapy. Population in 2013. https://www.renalreg.org/wp-content/uploads/2014/12/04-Chap-04.pdf https://www.renalreg.org/wp-content/uploads/2014/12/04-Chap-04.pdf (Accessed on February 18, 2015).</li><li class="breakAll">https://renal.org/audit-research/annual-report/22nd-annual-report-data-31122018 (Accessed on July 25, 2021).</li><li class="breakAll">North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) 2014 Annual Transplant Report. Emmes Corp., Rockville, MD. https://web.emmes.com/study/ped/annlrept/annualrept2014.pdf (Accessed on July 05, 2016).</li><li class="breakAll">www.anzdata.org.au/report/anzdata-43rd-annual-report-2020-data-to-2019/ (Accessed on July 25, 2021).</li><li class="breakAll">https://renal.org/audit-research/annual-report/22nd-annual-report-data-31122018, accesses 25/07/2021 (Accessed on July 25, 2021).</li><li class="breakAll">US Renal Data System. The Concise 2009 Annual Data Report: Atlas of Chronic kidney disease and End-stage Renal Disease in the US. National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 2009.</li><li><a class="nounderline abstract_t">Lewis MA, Shaw J, Sinha M, et al. UK Renal Registry 11th Annual Report (December 2008): Chapter 13 Demography of the UK paediatric renal replacement therapy population. Nephron Clin Pract 2009; 111 Suppl 1:c257.</a></li><li class="breakAll">NAPRTCS: 2008 Annual Report, Rockville, MD. http://www.emmes.com/study/ped/annlrept/Annual%20Report%20-2008.pdf (Accessed on March 14, 2011).</li><li><a class="nounderline abstract_t">McDonald SP, Craig JC, Australian and New Zealand Paediatric Nephrology Association. Long-term survival of children with end-stage renal disease. N Engl J Med 2004; 350:2654.</a></li><li><a class="nounderline abstract_t">Gillen DL, Stehman-Breen CO, Smith JM, et al. Survival advantage of pediatric recipients of a first kidney transplant among children awaiting kidney transplantation. Am J Transplant 2008; 8:2600.</a></li><li><a class="nounderline abstract_t">Galiyeva DB, Jackson CA, Wild SH, et al. Long-term all-cause mortality and cardiovascular outcomes in Scottish children after initiation of renal replacement therapy: a national cohort study. Pediatr Nephrol 2020; 35:677.</a></li><li><a class="nounderline abstract_t">Marlais M, Martin K, Marks SD. Improved renal allograft survival for pre-emptive paediatric renal transplant recipients in the UK. Arch Dis Child 2021; 106:1191.</a></li><li><a class="nounderline abstract_t">Kramer A, Stel VS, Tizard J, et al. Characteristics and survival of young adults who started renal replacement therapy during childhood. Nephrol Dial Transplant 2009; 24:926.</a></li><li class="breakAll">Kennedy S, Briggs N, Dent, H et al. Chapter 11: Paediatric in Australia and New Zealand Dialysis and Transplant Registry. http://www.anzdata.org.au/anzdata/AnzdataReport/35thReport/2012c11_paediatric_v1.9.pdf (Accessed on February 26, 2015).</li><li><a class="nounderline abstract_t">Warady BA, Alexander SR, Watkins S, et al. Optimal care of the pediatric end-stage renal disease patient on dialysis. Am J Kidney Dis 1999; 33:567.</a></li><li><a class="nounderline abstract_t">Verrina E, Cappelli V, Perfumo F. Selection of modalities, prescription, and technical issues in children on peritoneal dialysis. Pediatr Nephrol 2009; 24:1453.</a></li><li><a class="nounderline abstract_t">Favel K, Dionne JM. Factors influencing the timing of initiation of renal replacement therapy and choice of modality in children with end-stage kidney disease. Pediatr Nephrol 2020; 35:145.</a></li><li><a class="nounderline abstract_t">Sadowski RH, Harmon WE, Jabs K. Acute hemodialysis of infants weighing less than five kilograms. Kidney Int 1994; 45:903.</a></li><li><a class="nounderline abstract_t">Carey WA, Talley LI, Sehring SA, et al. Outcomes of dialysis initiated during the neonatal period for treatment of end-stage renal disease: a North American Pediatric Renal Trials and Collaborative Studies special analysis. Pediatrics 2007; 119:e468.</a></li><li><a class="nounderline abstract_t">Tsai TC, Liu SI, Tsai JD, Chou LH. Psychosocial effects on caregivers for children on chronic peritoneal dialysis. Kidney Int 2006; 70:1983.</a></li><li><a class="nounderline abstract_t">Wightman A, Zimmerman CT, Neul S, et al. Caregiver Experience in Pediatric Dialysis. Pediatrics 2019; 143.</a></li><li><a class="nounderline abstract_t">Rees L, Schaefer F, Schmitt CP, et al. Chronic dialysis in children and adolescents: challenges and outcomes. Lancet Child Adolesc Health 2017; 1:68.</a></li><li><a class="nounderline abstract_t">Vidal E, Chesnaye NC, Paglialonga F, et al. A propensity-matched comparison of hard outcomes in children on chronic dialysis. Eur J Pediatr 2018; 177:117.</a></li><li><a class="nounderline abstract_t">Weaver DJ Jr, Somers MJG, Martz K, Mitsnefes MM. Clinical outcomes and survival in pediatric patients initiating chronic dialysis: a report of the NAPRTCS registry. Pediatr Nephrol 2017; 32:2319.</a></li><li><a class="nounderline abstract_t">Jain AK, Blake P, Cordy P, Garg AX. Global trends in rates of peritoneal dialysis. J Am Soc Nephrol 2012; 23:533.</a></li><li><a class="nounderline abstract_t">Ma A, Shroff R, Hothi D, et al. A comparison of arteriovenous fistulas and central venous lines for long-term chronic haemodialysis. Pediatr Nephrol 2013; 28:321.</a></li><li><a class="nounderline abstract_t">Baracco R, Mattoo T, Jain A, et al. Reducing central venous catheters in chronic hemodialysis--a commitment to arteriovenous fistula creation in children. Pediatr Nephrol 2014; 29:2013.</a></li><li><a class="nounderline abstract_t">Clinical practice recommendation 8: vascular access in pediatric patients. Am J Kidney Dis 2006; 48 Suppl 1:S274.</a></li><li><a class="nounderline abstract_t">Borzych-Duzalka D, Shroff R, Ariceta G, et al. Vascular Access Choice, Complications, and Outcomes in Children on Maintenance Hemodialysis: Findings From the International Pediatric Hemodialysis Network (IPHN) Registry. Am J Kidney Dis 2019; 74:193.</a></li><li class="breakAll">2018 USRDS Annual Data Report. www.usrds.org/adr.aspx (Accessed on September 09, 2019).</li><li><a class="nounderline abstract_t">Warady BA, Bakkaloglu S, Newland J, et al. Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update. Perit Dial Int 2012; 32 Suppl 2:S32.</a></li><li class="breakAll">North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) 2011 Annual Dialysis Report. Emmes Corp., Rockville, MD. https://web.emmes.com/study/ped/annlrept/annualrept2011.pdf (Accessed on July 05, 2016).</li><li><a class="nounderline abstract_t">Atkinson MA, Oberai PC, Neu AM, et al. Predictors and consequences of higher estimated glomerular filtration rate at dialysis initiation. Pediatr Nephrol 2010; 25:1153.</a></li><li><a class="nounderline abstract_t">Dart AB, Zappitelli M, Sood MM, et al. Variation in estimated glomerular filtration rate at dialysis initiation in children. Pediatr Nephrol 2017; 32:331.</a></li><li><a class="nounderline abstract_t">Preka E, Bonthuis M, Harambat J, et al. Association between timing of dialysis initiation and clinical outcomes in the paediatric population: an ESPN/ERA-EDTA registry study. Nephrol Dial Transplant 2019; 34:1932.</a></li><li><a class="nounderline abstract_t">Cooper BA, Branley P, Bulfone L, et al. A randomized, controlled trial of early versus late initiation of dialysis. N Engl J Med 2010; 363:609.</a></li><li><a class="nounderline abstract_t">Winnicki E, McCulloch CE, Mitsnefes MM, et al. Use of the Kidney Failure Risk Equation to Determine the Risk of Progression to End-stage Renal Disease in Children With Chronic Kidney Disease. JAMA Pediatr 2018; 172:174.</a></li><li><a class="nounderline abstract_t">Winnicki E, Johansen KL, Cabana MD, et al. Higher eGFR at Dialysis Initiation Is Not Associated with a Survival Benefit in Children. J Am Soc Nephrol 2019; 30:1505.</a></li></ol></div><div id="topicVersionRevision">Topic 16179 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11904577" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29653769" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Estimating Time to ESRD in Children With CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21713524" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Epidemiology of chronic kidney disease in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33483800" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Ten-year trends in epidemiology and outcomes of pediatric kidney replacement therapy in Europe: data from the ESPN/ERA-EDTA Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33483800" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Ten-year trends in epidemiology and outcomes of pediatric kidney replacement therapy in Europe: data from the ESPN/ERA-EDTA Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29273970" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Renal replacement therapy for children throughout the world: the need for a global registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26498279" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Lessons learned from the ESPN/ERA-EDTA Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26498279" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Lessons learned from the ESPN/ERA-EDTA Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26498279" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Lessons learned from the ESPN/ERA-EDTA Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26498279" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Lessons learned from the ESPN/ERA-EDTA Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26498279" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Lessons learned from the ESPN/ERA-EDTA Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26498279" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Lessons learned from the ESPN/ERA-EDTA Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26498279" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Lessons learned from the ESPN/ERA-EDTA Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19542701" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : UK Renal Registry 11th Annual Report (December 2008): Chapter 13 Demography of the UK paediatric renal replacement therapy population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19542701" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : UK Renal Registry 11th Annual Report (December 2008): Chapter 13 Demography of the UK paediatric renal replacement therapy population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15215481" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Long-term survival of children with end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18808405" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Survival advantage of pediatric recipients of a first kidney transplant among children awaiting kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31845058" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Long-term all-cause mortality and cardiovascular outcomes in Scottish children after initiation of renal replacement therapy: a national cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34016592" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Improved renal allograft survival for pre-emptive paediatric renal transplant recipients in the UK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18840894" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Characteristics and survival of young adults who started renal replacement therapy during childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18840894" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Characteristics and survival of young adults who started renal replacement therapy during childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10070923" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Optimal care of the pediatric end-stage renal disease patient on dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18521632" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Selection of modalities, prescription, and technical issues in children on peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31654222" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Factors influencing the timing of initiation of renal replacement therapy and choice of modality in children with end-stage kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8196295" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Acute hemodialysis of infants weighing less than five kilograms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17224455" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Outcomes of dialysis initiated during the neonatal period for treatment of end-stage renal disease: a North American Pediatric Renal Trials and Collaborative Studies special analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16985519" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Psychosocial effects on caregivers for children on chronic peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30696758" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Caregiver Experience in Pediatric Dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30169229" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Chronic dialysis in children and adolescents: challenges and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29143935" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A propensity-matched comparison of hard outcomes in children on chronic dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28762101" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Clinical outcomes and survival in pediatric patients initiating chronic dialysis: a report of the NAPRTCS registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22302194" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Global trends in rates of peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23052655" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A comparison of arteriovenous fistulas and central venous lines for long-term chronic haemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24474576" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Reducing central venous catheters in chronic hemodialysis--a commitment to arteriovenous fistula creation in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16813992" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Clinical practice recommendation 8: vascular access in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31010601" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Vascular Access Choice, Complications, and Outcomes in Children on Maintenance Hemodialysis: Findings From the International Pediatric Hemodialysis Network (IPHN) Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31010601" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Vascular Access Choice, Complications, and Outcomes in Children on Maintenance Hemodialysis: Findings From the International Pediatric Hemodialysis Network (IPHN) Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22851742" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22851742" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20191370" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Predictors and consequences of higher estimated glomerular filtration rate at dialysis initiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27695987" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Variation in estimated glomerular filtration rate at dialysis initiation in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31038179" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Association between timing of dialysis initiation and clinical outcomes in the paediatric population: an ESPN/ERA-EDTA registry study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20581422" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : A randomized, controlled trial of early versus late initiation of dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29255845" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Use of the Kidney Failure Risk Equation to Determine the Risk of Progression to End-stage Renal Disease in Children With Chronic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31320460" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Higher eGFR at Dialysis Initiation Is Not Associated with a Survival Benefit in Children.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
